Literature DB >> 29948346

Association between the -174 C/G polymorphism in the interleukin-6 (IL-6) gene and gastrointestinal involvement in patients with systemic sclerosis.

Ana Zekovic1, Misa Vreca2, Vesna Spasovski2, Marina Andjelkovic2, Sonja Pavlovic2, Nemanja Damjanov3,4.   

Abstract

Genetic predisposition to systemic sclerosis (SSc) has still not been fully revealed. Interleukin-6 (IL-6) is a mediator of T cell proliferation and fibrotic events in SSc. Polymorphisms in the IL-6 are found to be important in susceptibility to development of SSc. We aimed to assess the frequency of -174 C/G of IL-6 gene polymorphism in SSc patients and healthy controls, as well as correlation with disease manifestations. In the case-control study, 102 patients with SSc and 93 controls were included. PCR-RFLP method was performed for genotyping promotor variants -174 C/G of IL-6 gene. The expression level of IL-6 was determined by qRT-PCR on subset of 50 patients and 13 healthy controls with different IL-6 genotypes. We used UCLA GIT 2.0 questionnaire to assess gastrointestinal involvement in SSc patients. The expression level of IL-6 gene was significantly higher in patients with SSc in comparison with healthy controls (p < 0.05). Carriers of C-allele of IL-6 gene compared to those with G allele, showed higher expression of IL-6 gene (95.8 vs. 41.2, p < 0.05), higher GIT total score (0.85 vs. 0.5, p < 0.05) and higher distension scale score (1.4 ± 0.9 vs. 0.78 ± 0.8, p = 0.05). No significant differences in genotype distribution and allele frequency were observed between patients and controls. The expression of IL6 gene varies significantly during the course of SSc. The IL-6 gene variant -174 C/G (presence of C-allele) is associated with higher IL-6 gene expression and greater GIT impairment in patients with SSc.

Entities:  

Keywords:  GI involvement; IL6-gene polymorphism; Systemic sclerosis

Mesh:

Substances:

Year:  2018        PMID: 29948346     DOI: 10.1007/s10067-018-4163-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  44 in total

1.  CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study.

Authors:  A Antonelli; C Ferri; P Fallahi; S M Ferrari; D Giuggioli; M Colaci; A Manfredi; S Frascerra; F Franzoni; F Galetta; E Ferrannini
Journal:  Rheumatology (Oxford)       Date:  2008-01       Impact factor: 7.580

2.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

Review 3.  Gastrointestinal involvement in systemic sclerosis.

Authors:  Edoardo Savarino; Manuele Furnari; Nicola de Bortoli; Irene Martinucci; Giorgia Bodini; Massimo Ghio; Vincenzo Savarino
Journal:  Presse Med       Date:  2014-08-29       Impact factor: 1.228

4.  Interleukin-6 gene promoter methylation in rheumatoid arthritis and chronic periodontitis.

Authors:  Kohei Ishida; Tetsuo Kobayashi; Satoshi Ito; Yasutaka Komatsu; Tomoko Yokoyama; Moe Okada; Asami Abe; Akira Murasawa; Hiromasa Yoshie
Journal:  J Periodontol       Date:  2011-11-28       Impact factor: 6.993

5.  Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis.

Authors:  S Sato; M Hasegawa; K Takehara
Journal:  J Dermatol Sci       Date:  2001-10       Impact factor: 4.563

Review 6.  Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature.

Authors:  Tracy M Frech; Marie Hudson
Journal:  Clin Exp Rheumatol       Date:  2015-09-01       Impact factor: 4.473

Review 7.  Gastrointestinal motility disorders in scleroderma.

Authors:  R W Sjogren
Journal:  Arthritis Rheum       Date:  1994-09

8.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

Review 9.  Interleukin-6: a new therapeutic target in systemic sclerosis?

Authors:  Steven O'Reilly; Rachel Cant; Marzena Ciechomska; Jacob M van Laar
Journal:  Clin Transl Immunology       Date:  2013-04-12

10.  Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.

Authors:  A Strangfeld; A Richter; B Siegmund; P Herzer; K Rockwitz; W Demary; M Aringer; Y Meißner; A Zink; J Listing
Journal:  Ann Rheum Dis       Date:  2016-07-12       Impact factor: 19.103

View more
  1 in total

Review 1.  Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?

Authors:  Anca Cardoneanu; Alexandra Maria Burlui; Luana Andreea Macovei; Ioana Bratoiu; Patricia Richter; Elena Rezus
Journal:  Biomedicines       Date:  2022-01-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.